Evidence map›Paper›PMID 41523999›Full record

ArticleInternational journal of ophthalmology2026

Pathophysiology of sildenafil-induced ocular toxicity in rats and treatment.

Ibrahim Cicek, Busra Caliskan, Bulent Yavuzer, Durdu Altuner, Tugba Bal Tastan, Taha Abdulkadir Coban, Ezgi Karatas, Halis Suleyman

Abstract read
In one paragraph

Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ibrahim CicekDepartment of Ophthalmology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Türkiye.
Busra CaliskanDepartment of Ophthalmology, Faculty of Medicine, Ataturk University, Erzurum 25240, Türkiye.
Bulent YavuzerDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Türkiye.
Durdu AltunerDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Türkiye.
Tugba Bal TastanDepartment of Histology and Embryology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Türkiye.
Taha Abdulkadir CobanDepartment of Biochemistry, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Türkiye.
Ezgi KaratasDepartment of Ophthalmology, Faculty of Medicine, Agri Ibrahim Cecen University, Agri 04100, Türkiye.
Halis SuleymanDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo examine the ocular toxicity linked to sildenafil usage and the possible protective benefits of adenosine triphosphate (ATP) against this toxicity in rats.

methodsTwenty-four male albino Wistar-type rats were divided into four equal groups (

resultsSildenafil increased oxidant (malondialdehyde) levels and decreased antioxidant levels (total glutathione, superoxide dismutase, catalase) in rat ocular tissues and caused severe oxidative stress. In addition, sildenafil has been shown histopathologically to cause oxidative damage in retinal layers. ATP treatment suppressed oxidative stress and attenuated histopathological damage in the retinal layers.

conclusionATP protects retinal tissue against sildenafil-induced ocular oxidative damage in rats and may contribute to the development of novel approaches to prevent or treat this damage.

Indexed as

adenosine triphosphateocular toxicityoxidative stressratsretinasildenafil

Identifiers

PMID41523999
PMCPMC12782068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.